Faron Pharmaceuticals Oy (HEL:FARON)
Finland · Delayed Price · Currency is EUR | Market Cap | 96.78M -68.0% |
| Revenue (ttm) | n/a |
| Net Income | -27.26M |
| EPS | -0.24 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,146,900 |
| Average Volume | 1,154,507 |
| Open | 0.4675 |
| Previous Close | 0.4660 |
| Day's Range | 0.4490 - 0.4675 |
| 52-Week Range | 0.4365 - 3.3450 |
| Beta | 1.18 |
| RSI | 33.52 |
| Earnings Date | Aug 26, 2026 |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. The company’s lead product candidate is Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-associated macrophages and converts the highly immunosuppressive M2-like macrophages to a pro-inflammatory state to promote immune activation. It is also developing bexmarilimab for the treatment of hematological and solid tumor cancers; and in combination with care therapies, azacitidine, and other hypomethylating agents... [Read more]
Financial Performance
Financial StatementsNews
Faron Pharmaceuticals Oy Transcript: Investor update
Bexmarilimab targets CLEC-1 on macrophages, showing strong efficacy and safety in high-risk MDS, with a 45% CR rate and extended survival. A €40 million fully committed rights offering will fund a pivotal phase IIb trial and multiple solid tumor studies, positioning the asset for major commercial and partnership opportunities.
Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2025 Earnings Call Highlights: Clinical Successes ...
Faron Pharmaceuticals Oy (FRA:4FR) Full Year 2025 Earnings Call Highlights: Clinical Successes and Financial Challenges
Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript
Full Year 2025 Faron Pharmaceuticals Oy Earnings Call Transcript
Faron Pharmaceuticals Oy Earnings Call Transcript: H2 2025
Outstanding clinical results in high-risk MDS, improved financial position, and a robust pipeline set the stage for a pivotal phase 2b trial and expansion into new indications. Planned EUR 40 million rights offering aims to fund key milestones.
Faron Pharmaceuticals Oy Transcript: Investor update
High and durable response rates in high-risk MDS have led to a revised, de-risked trial design using CR as the approval endpoint, supported by FDA guidance. Partnering interest is strong, with a new value inflection point expected from Phase II data in November.
Faron Pharmaceuticals Oy Transcript: ESMO 2025 Conference
Bexmarilimab plus azacitidine demonstrated strong efficacy and safety in high-risk and HMA-failed MDS, with particularly high response rates in low blast count patients. A pivotal phase 2/3 trial is planned, and development is expanding into AML, solid tumors, and autoimmune indications.
Faron Pharmaceuticals Oy Earnings Call Transcript: H1 2025
H1 2025 saw major clinical and financial progress, highlighted by positive phase II results for BEX in high-risk MDS, a strong cash position, and FDA alignment on a pivotal trial with accelerated approval possible in 2028. The oncology pipeline expanded, and new financing secured.
Faron Pharmaceuticals To Earn Spotlight At IUIS 2025 With Its Bexmarilimab Data
At IUIS 2025, Dr. Mika Kontro, MD, PhD, will deliver a presentation titled "Efficacy of Macrophage Checkpoint Clever-1 Inhibition with bexmarilimab plus Azacitidine in Myelodysplastic Syndrome: Result...
Faron Pharmaceuticals Oy Transcript: Study Result
Phase 2 results for bexmarilimab plus azacitidine in high-risk MDS show strong response rates and favorable safety, including in TP53-mutant patients. The FDA supports a single pivotal Phase 3 trial, with plans to initiate in H1 next year and potential for accelerated approval if interim results are positive.
Faron Pharmaceuticals Oy Earnings Call Transcript: H2 2024
Cash position improved with €35.5M raised in 2024 and €12M in early 2025, while losses narrowed. Bexmarilimab advanced with strong clinical results and multiple regulatory fast-tracks; phase 2 top-line data is expected in April 2025.
Faron Pharmaceuticals Oy Transcript: Study Update
Interim results from the BEXMAB trial in relapsed/refractory MDS show an 80% overall response rate, excellent safety, and a median survival of 13.4 months, outperforming current therapies. Regulatory designations and trial expansion support rapid development and future phase III plans.
Faron Pharmaceuticals Oy Transcript: CMD 2024
Bexmarilimab is advancing as a potential cornerstone therapy for cancers with CLEVER-1 macrophage-driven resistance, with strong phase II MDS data, robust market enthusiasm, and a strategic focus on cost-effective proof-of-concept trials. Key milestones include a pivotal phase II readout and solid tumor trial launches.
Faron Pharmaceuticals Oy Earnings Call Transcript: H1 2024
H1 saw record fundraising, leadership changes, and strong clinical progress, including FDA Fast Track for bexmarilimab. Cash runway extends into Q1 2025, but additional funding or partnership is needed for phase III.